Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome

Fertility and Sterility

Volumn 82, Issue SUPPL. 1, 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ENZYME ACTIVITY; GASTROINTESTINAL DISEASE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIFESTYLE; LIVER NECROSIS; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; STEROIDOGENESIS;

EID: 4444321538     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2004.05.041     Document Type: Article

References (24)

1. Rosenfield R.L. Current concepts of polycystic ovary syndrome. Baillere's Clin Obstet Gynaecol. 11:1997;307-333
2. Ehrmann D.A. Relation of functional hyperandrogenism to non-insulin dependent diabetes mellitus. Baillere's Clin Obstet Gynaecol. 11/2:1997;335-347
3. Nestler J.E. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome and its clinical implications. Semin Reprod Endocrinol. 15:1997;111-122
4. Legro R.S., Finegood D., Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 83:1998;2694-2698
5. Nestler JE. Insulin regulation of human ovarian androgens. Hum Reprod 1997;(Suppl 1):53-62
6. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1989;1165-1174
7. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:1996;617-623
8. Huber-Buchholz M.M., Carey D.G., Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 84:1999;1470-1474
9. Davison R.M. New approaches to insulin resistance in polycystic ovarian syndrome. Curr Opin Obstet Gynecol. 10:1998;193-198
10. Sattar N., Hopkinson Z.E., Greer I.A. Insulin-sensitizing agents in polycystic-ovary syndrome. Lancet. 351:1998;305-307
11. Antonucci T., Whitcomb R., McLain R., Lockwood D., Norris R.M. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care. 20:1998;188-193
12. Henry R.R. Thiazolidinediones. Endocrinol Metab Clin North Am. 26:1997;553-573
13. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 331:1994;1188-1193
14. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669
15. Diamanti-Kandarakis E., Kouli C., Tsianateli T., Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 138:1998;269-274
16. Velazquez E., Acosta A., Mendoza S.G. Menstrual cyclicity after metformin in polycystic ovary syndrome. Obstet Gynecol. 90:1997;392-395
17. Nestler J.E., Jakubowicz D.J., Evans W.S., Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 338:1998;1876-1880
18. Velazquez E., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654
19. Ehrmann D.A., Cavaghan M.K., Imperial J., Sturis J., Rosenfield R.L., Polonsky K.S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;524-530
20. Chen C., Frazier J. Troglitazone an antidiabetic agent. Am J Health Syst Pharm. 55:1998;905-925
21. Spiegelman B.M. PPAR-gamma adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514
22. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:1996;3299-3306
23. Ehrmann D.A., Schneider D.J., Sobel B.E., Cavaghan M.K., Imperial J., Rosenfield R.L., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;2108-2116
24. Coetzee E.J., Jackson W.P. Metformin in management of pregnant insulin-dependent diabetics. Diabetologia. 16:1979;241-245